GlassScriptPhysician profile
Zhigao Huang
NPI 1861461964
$612,634.85
in general payments reported to CMS, 2019-2025
73 companies · $63K in 2025
The $63K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123K · 2020: $93K · 2021: $88K · 2022: $98K · 2023: $89K · 2024: $59K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Honoraria: $38K · Consulting Fee: $26K · Food and Beverage: $13K · Travel and Lodging: $11K · Education: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,370.38 |
| Honoraria | $38,160.00 |
| Consulting Fee | $25,537.50 |
| Food and Beverage | $13,246.18 |
| Travel and Lodging | $10,538.17 |
| Education | $1,475.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $147,007.16 | 2019-2025 | Gocovri, Apokyn, Gocovri |
| Teva Pharmaceuticals USA, INC. | $144,558.38 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $125,309.09 | 2019-2025 | Ingrezza, Ongentys |
| Adamas Pharmaceuticals, INC. | $57,343.33 | 2019-2021 | |
| Allergan, INC. | $39,568.39 | 2019-2022 | |
| Abbvie INC. | $29,846.34 | 2019-2025 | |
| Acorda Therapeutics, INC | $25,244.64 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $15,284.77 | 2019-2025 | Nuplazid |
| Kyowa Kirin, INC. | $6,805.74 | 2019-2023 | Nourianz |
| Sunovion Pharmaceuticals INC. | $5,923.17 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $4,739.91 | 2019-2025 | Ongentys, Ongentys 50mg Capsules 30, Crexont |
| Amgen INC. | $1,288.29 | 2019-2024 | Aimovig |
| Vertex Pharmaceuticals Incorporated | $826.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $820.63 | 2019-2025 | |
| Eisai INC. | $735.45 | 2019-2025 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhigao Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.